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Background: Accumulating evidence suggests that dysfunction in the glutamatergic system may underlie the
pathophysiology of autism. The anterior cingulate cortex (ACC) has been implicated in autism as well as in
glutamatergic neurotransmission. We hypothesized that alterations in the glutamate-glutamine cycle in the ACC
might play a role in the pathophysiology of autism.
Methods: We performed Western blot analyses for the protein expression levels of enzymes in the glutamate-glutamine
cycle, including glutamine synthetase, kidney-type glutaminase, liver-type glutaminase, and glutamate dehydrogenases 1
and 2, in the ACC of postmortem brain of individuals with autism (n = 7) and control subjects (n = 13).
Results: We found that the protein levels of kidney-type glutaminase, but not those of the other enzymes measured, in
the ACC were significantly lower in subjects with autism than in controls.
Conclusion: The results suggest that reduced expression of kidney-type glutaminase may account for putative
alterations in glutamatergic neurotransmission in the ACC in autism.
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Autism is a neurodevelopmental disorder that is characte-
rized by severe and sustained impairment in social inter-
action, deficits in verbal and nonverbal communication,
and repetitive and restricted patterns of behavior and inter-
ests [1]. One region that has been implicated in the patho-
physiology of autism is the anterior cingulate cortex (ACC),
an area crucial for social cognitive processes [2-4]. Neuro-
imaging studies using magnetic resonance imaging and/or
positron emission tomography have suggested structural
and functional alterations in the ACC of people with autism
[5-8]. For instance, Haznedar and colleagues [9] reported
that the ACC was significantly smaller in relative volume,
and metabolically less active, in individuals with autism
than in normal subjects. Furthermore, a meta-analysis of
functional neuroimaging studies for autism and related* Correspondence: k-suzuki@hama-med.ac.jp
1Research Center for Child Mental Development, Hamamatsu University
School of Medicine, Hamamatsu, Japan
Full list of author information is available at the end of the article
© 2013 Shimmura et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumdisorders, namely, autism spectrum disorders (ASDs), re-
vealed that subjects with ASD showed a greater likelihood
of hypoactivation in the ACC compared with that of con-
trols [10]. It is speculated that at least some of these find-
ings are attributable to abnormalities in glutamatergic
neurotransmission, because both efferents from the ACC
to the ventral striatum and afferents from the thalamus to
ACC neurons are mediated by a neurotransmitter, glutam-
ate [11]. Postmortem studies have suggested that dysfunc-
tion in the glutamatergic system in the cerebellum may be
involved in the pathophysiology of autism [12]. For in-
stance, Purcell and colleagues [13] reported that the mRNA
levels of genes, including those for the excitatory amino
acid transporter 1 and AMPA-type glutamate receptor, are
significantly increased in the postmortem cerebellum of
autistic individuals, while AMPA-type glutamate receptor
density is somewhat decreased in people with autism. Thus,
extracellular glutamate levels in the cerebellum of people
with autism may be extremely high [14,15]. However, it
remains unclear whether or not a similar profile applies totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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resonance spectroscopy (1H-MRS) study, Bernardi and
colleagues [16] reported a reduction in Glx, a measure of
the mixture of glutamate and glutamine, in the right ACC
of adults with ASD, although another 1H-MRS study
revealed no such difference in Glx in the ACC of children
with ASD [17]. Such inconsistent results might be attribut-
able to differences in the age range of the subjects studied
and/or in the resolution of the equipment used.
Glutamate is synthesized from glutamine by glutamin-
ase in neurons of the brain. After the glutamate is released
from the synaptic terminal, it is taken up into astrocytes,
where it is converted into glutamine by glutamine synthe-
tase; the glutamine is then transported to the neurons and
reused. This ‘glutamate-glutamine cycle’ is an important
constituent of the glutamatergic neurotransmission
system. On the basis of these findings, we hypothesized
that the glutamate-glutamine cycle is impaired in the
brains of autistic individuals, and that the enzymes associ-
ated with this cycle are dysregulated. To probe for direct
evidence of any differences in the levels of glutamate-
glutamine cycle-related enzymes between the brain of
individuals with autism and that of healthy subjects, we
examined here the protein levels of the following enzymes
associated with the glutamate-glutamine cycle in the post-
mortem brains of individuals with autism: glutamine syn-
thetase (GS), which converts glutamate to glutamine;
kidney-type glutaminase (KGA), which synthesizes glu-
tamate from glutamine; liver-type glutaminase (LGA),
which is an isozyme dominant in the liver; and glutamate
dehydrogenases 1 (GDH1) and 2 (GDH2), both of which
synthesize glutamate from α-ketoglutarate. We also exam-
ined free glutamate and glutamine levels in the ACC of
postmortem brains of individuals with autism.
Methods
Postmortem brain tissues
The ethics committee of the Hamamatsu University
School of Medicine approved this study, in which all
experimental procedures were carried out in compliance
with the Declaration of Helsinki. Postmortem cingulate
blocks were obtained from the Autism Tissue Program
(Princeton, NJ, USA) and the NICHD Brain and Tissue
Bank for Developmental Disorders (Baltimore, MD,
USA) (n = 7 autistic brain samples from six males and a
female; n = 13 control brain samples from nine males
and four females). The demographic characteristics are
shown in Table 1. We have chosen samples from donors
with relatively wide age range, from children to adults,
in order to examine possible effects of age on the levels
of expression of enzymes as well as concentrations of
amino acids. Samples were matched for age, gender, and
postmortem interval (PMI). Autism was diagnosed
according to the DSM-IV-TR, and the diagnosis wasconfirmed by the Autism Diagnostic Interview - revised.
All samples were stored at −80°C until use. Information
obtained from the next of kin showed that none of the
controls had any known history of neuropsychiatric
disorders or illicit drug use.
Western blotting
Brain tissue (approximately 50 mg) from each subject
was cut and placed in ice-cold RIPA buffer containing
protease inhibitor cocktail (Complete Protease Inhibitor
Cocktail Tablets; Roche, Basel, Switzerland). Tissue
samples were homogenized by sonication while the
temperature was maintained at 4°C. The homogenates
were centrifuged at 10,000 × g for 20 minutes at 4°C.
The supernatants were collected, and the total protein
content was assayed using the BCA protein assay
(Thermo Scientific, Waltham, MA, USA).
Ten micrograms of each brain lysate was loaded onto
a 7.5% SDS-PAGE. The proteins were electroblotted
onto PVF membrane (Millipore, Billerica, MA, USA).
Protein blots were washed and blocked for one hour at
room temperature with 1% nonfat dry milk in tris-buffered
saline (pH= 7.4). The following proteins were analyzed: GS,
KGA, LGA, GDH1, GDH2, glial fibrillary acidic protein
(GFAP) as a marker of astrocyte [18], neuron-specific
enolase (NSE) as a marker of neuronal integrity [19], and
ß-actin served as an internal control. The blots were incu-
bated with primary antibody overnight at 4°C (anti-GS, 1:
2000, from Abcam, (Cambridge, UK); anti-KGA; 1: 1000,
from Protein Tech Group Inc. (Chicago, IL, USA); anti-
LGA, 1: 400, from Aviva Systems Biology (San Diego, CA,
USA); anti-GDH1, 1: 1000, from Abcam (Cambridge, UK);
anti-GDH2, 1: 500, from Abnova (Taipei, Taiwan); anti-
GFAP, 1: 4000, from Chemicon International (Temecula,
CA, USA); anti-NSE, 1: 2000 and anti-ß-actin, 1: 2000, both
from Abcam (Cambridge, UK), followed by horseradish
peroxidase-conjugated secondary antibody incubation for
one hour at room temperature. The immune complexes
were visualized using the ECL Plus detection system (GE
Healthcare, Buckinghamshire, UK) and were exposed to
Fuji medical x-ray film (Fuji Photo Film, Tokyo, Japan).
Measurement of amino acids
An examiner who was blinded to the diagnosis used high-
performance liquid chromatography (HPLC) to measure
free glutamate and glutamine in postmortem brain tissues.
The brain tissues were homogenized in 20 volumes of
methanol (HPLC grade) on ice. The homogenates were
centrifuged at 4,500 × g for 10 minutes, and 20 μL of super-
natant was evaporated to dryness at 40°C. To the residue,
20 μL of water (H2O) (HPLC grade), 20 μL of 0.1 mol/L
borate buffer (pH = 8.0), and 60 μL of 50 mmol/L 4-
fluoro-7-nitro-2,1,3-benzoxadiazole (Tokyo Kasei Kogyo
Co. Ltd., Tokyo, Japan) in acetonitrile (CH3CN) (HPLC
Table 1 Demographic variables for control subjects and individuals with autism
Case number Disorder Age (years) Gender PMI (hours) Cause of death History of seizures
C01 No known disorder 27 M 10 Multiple injuries No
C02 No known disorder 15 M 12 N/A No
C03 No known disorder 15 M 16 Multiple injuries No
C04 No known disorder 9 F 20 Asthma No
C05 No known disorder 20 F 19 Head injuries No
C06 No known disorder 20 M 22 Multiple injuries No
C07 No known disorder 8 F 20 Traumatic multiple injury No
C08 No known disorder 14 M 18 Multiple injuries No
C09 No known disorder 12 M 19 Drowning No
C10 No known disorder 8 M 5 Cardiac arrhythmia No
C11 No known disorder 29 M 13 Traumatic multiple injuries No
C12 No known disorder 15 F 5 Chest injuries No
C13 No known disorder 14 M 16 Multiple injuries No
Control (n = 13) 15.8 ± 6.6 M:F = 9:4 15.0 ± 5.6
A01 Autism 9 M 13 Drowning No
A02 Autism 8 M 12 Drowning No
A03 Autism 8 M 16 Drowning No
A04 Autism 14 M 9 Drowning No
A05 Autism 27 M 8.3 Drowning No
A06 Autism 16 M N/A Seizures Yes
A07 Autism 29 F 17.83 Seizures Yes
Autism (n = 7) 15.9 ± 8.9 M:F = 6:1 12.7 ± 3.8
Values are shown as means ± standard deviation.
Abbreviations: F, female; M, male; N/A, not available; PMI, postmortem interval.
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heated at 60°C for one min and immediately
supplemented with 100 μL of H2O/CH3CN (90/10)
containing 0.1% trifluoroacetic acid to stop the reac-
tion. The resultant solution was injected into the
HPLC system in a volume of 10 μL.Statistical analysis
Each expression value of the enzymes using Western
blotting was normalized by the ß-actin level. The
Mann–Whitney U test was employed, and a two-
tailed P-value was established to test for significance.
The gender difference between the two groups was
examined by Fisher's exact test. The relationships
among the enzyme expression values and the rela-
tionships between enzyme expression values and age
or PMI were evaluated by Spearman’s ρ correlation
coefficients. The between-group differences in the
level of each amino acid were analyzed using the
Mann–Whitney U test. Data are expressed as mean ±
standard deviation. Statistical significance was set at
P < 0.05.Results
With regard to the postmortem brain tissues, there was
no significant difference in age (U = 42.5, P = 0.84), PMI
(U = 25.0, P = 0.23), or gender (P = 0.61) between the
autistic and control groups (Table 1). With respect to
the cause of death, five of the seven deaths of autistic
subjects were due to drowning. Among the controls,
nine of thirteen deaths were due to traumatic injury and
only one death was due to drowning. Two of the autistic
subjects had a history of epilepsy.
There were significant differences in the expression
levels of only one of the five enzymes, KGA, between
the autistic and control groups (U = 11.0, P = 0.007,
Figure 1). The mean KGA value was 34% lower in the
autistic group than in the control group. The KGA level
did not correlate with age or with PMI. The concentra-
tions of the remaining five proteins examined did not
differ between the two groups: GS, U = 24.0, P = 0.10;
LGA, U = 44.0, P = 0.93; GDH1, U = 27.0, P = 0.15;
GDH2, U = 38.0, P = 0.58; GFAP, U = 39.0, P = 0.63; and
NSE, U = 36.0, P = 0.48 (Figure 1). There was no statisti-
cally significant correlation between age of donors and
levels of LGA, GS, GDH1, GDH2, GFAP, or NSE (Table 2
Figure 1 Expression levels of enzymes associated with the glutamate-glutamine cycle. (A) Scatter plots of enzyme optical density values
for control subjects (n = 13) and individuals with autism (n = 7). Results are expressed as a percent of the control values, normalized by the β-actin
level. (B) Western blots showing immunolabeling of KGA, LGA, GS, GDH1, GDH2, GFAP, NSE, and β-actin in the anterior cingulate cortex (ACC) of
control subjects (n = 13) and individuals with autism (n = 7). Abbreviations: GDH1, glutamate dehydrogenase 1; GDH2, glutamate dehydrogenase 2;
GFAP, glial fibrillary acidic protein; GS, glutamine synthetase; KGA, kidney-type glutaminase; LGA, liver-type glutaminase; NSE, neuron-specific enolase.
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samples, case A7 received medication with sodium
valproate and topiramate. These anticonvulsants may
have affected the results. When case A7 was removed
from the analysis, the difference in KGA levels remainedTable 2 Results from correlation analyses between age of don
KGA LGA
Total sample (n = 20) Pearson r correlation coefficient -.14 .10
P-value .56 .68
Control (n = 13) Pearson r correlation coefficient -.24 .00
P-value .42 .98
Autism (n = 7) Pearson r correlation coefficient .22 -.13
P-value .66 .78
Abbreviations: GDH1, glutamate dehydrogenase 1; GDH2, glutamate dehydrogenas
glutamine synthetase; KGA, kidney-type glutaminase; LGA, liver-type glutaminase; Nsignificant between subjects with autism and controls
(U = 11.0, P = 0.015).
The tissue levels of glutamate and glutamine are
shown in Figure 2. There were no significant differences
between the two groups in free glutamate (7.8 ± 2.4ors and expression levels of proteins and amino acids
GS GDH1 GDH2 GFAP NSE Glu Gln Glu/Gln
-.13 -.04 .20 -.25 .22 .09 .35 -.32
.58 .87 .39 .29 .35 .72 .13 .17
-.30 -.07 -.07 -.44 .37 .34 .54 -.48
.32 .81 .80 .12 .21 .25 .06 .09
-.05 .05 .29 .14 .56 -.05 .07 -.16
.91 .90 .56 .78 .20 .90 .90 .71
e 2; GFAP, glial fibrillary acidic protein; Gln, glutamine; Glu, glutamate; GS,
SE, neuron-specific enolase.
Figure 2 Free glutamate and glutamine concentrations in the
ACC from brains of control and autistic subjects. There were no
significant differences in either glutamate or glutamine
concentrations between the two groups. The ratio of glutamate to
glutamine (Glu/Gln) was significantly lower in the autistic subjects
than in controls (U = 16.0, *P = 0.022). Abbreviations: Conc,
concentration; Gln, glutamine; Glu, glutamate; ns, not significant.
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nmol/mg tissue in the control group, U = 41.0, P = 0.75)
or glutamine levels (4.8 ± 1.4 nmol/mg tissue in the aut-
istic group versus 4.0 ± 0.8 nmol/mg tissue in the control
group, U = 25.0, P = 0.11). However, the ratio of glutam-
ate to glutamine (Glu/Gln ratio) was significantly smaller
in the autistic tissue than in the controls (1.54 ± 0.70 in
the autistic group versus 2.23 ± 0.30 in the control group,
U = 16.0, P = 0.022). There was no statistically significant
correlation between age and levels of glutamate, glutamine,
or Glu/Gln ratio (Table 2 and Additional file 2).
Discussion
In the present study, we found that KGA expression in
the ACC of postmortem brain tissue was significantly
lower in individuals with autism than in controls. In
contrast, no changes were observed in the other enzymes
examined; that is, LGA, GS, GDH1, and GDH2 levels
were the same in autism and control subjects. Further-
more, protein levels of either GFAP or NSE were not
different between the two groups. These results suggest
that KGA expression may be selectively reduced among
enzymes participating in the glutamate-glutamine cycle in
the ACC in individuals with autism.
The quality of proteins isolated from the postmortem
brain depends on the PMI and on the agonal state
preceding death by causes such as hypoxia or other
trauma to the brain [20]. It has been reported that PMI
had no effect on glutaminase levels in the postmortem
brain [21,22]. Given that there was no significant diffe-
rence in PMI between the two groups in the current
study, it is unlikely that the PMI influenced our results.
With regard to the cause of death, five of the seven
subjects with autism died by drowning, while the causeof mortality in most of the control cases was traumatic
injury. It is possible that the individuals who died from
drowning had been exposed to an ischemic or hypoxic
state for a longer duration than were those who died
due to traumatic injury. This, in turn, could have
affected the KGA expression levels. To the best of our
knowledge, there are no reports of specific KGA reductions
in tissue in an ischemic or hypoxic state. Further studies
are needed in this regard. It is also important to consider
the presence or absence of a history of seizures, because
glutamate plays an important role in the initiation and
propagation of epileptic seizures [23]. It has been reported
that patients with mesial temporal lobe epilepsy have
increased basal concentrations of extracellular glutamate in
the epileptogenic hippocampus [24]. Eid and colleagues
[25] have shown that protein levels of phosphate-activated
glutaminase (that is, KGA) in hippocampal homogenates
were not significantly different between patients with
mesial temporal lobe epilepsy and patients with other
forms of temporal lobe epilepsy (non-epileptogenic hippo-
campus). However, no information is currently available
regarding whether or not the expression of glutaminase in
the ACC is altered in patients with epilepsy. In our post-
mortem brain samples, A6 and A7 had a history of
epilepsy; KGA expression in A6 was a little higher than the
mean level in the autism group, whereas that in A7 was
lower. However, neither case was an outlier. Therefore, it is
unlikely that the history of epilepsy in these two cases con-
tributed to our results. With regard to the data for GDH2,
very low levels of expression were observed in three sam-
ples from autism while the remaining four samples showed
medium-high levels of expression. Since the variance in
GDH2 levels did not differ significantly between the two
groups, it is unclear from this preliminary study whether
the distribution of GDH2 levels in autism represents two
possible subgroups.
The findings of the present study suggested that KGA,
which converts glutamine into glutamate, is significantly
reduced in the ACC of individuals with autism. The
KGA isozyme, which is ubiquitous in all tissues, is
expressed predominantly in the mitochondria of neurons
in the brain [26]. In addition, no significant differences
were observed between the two groups in terms of the
expression levels of NSE, which served as markers for the
number of neurons. Therefore, our results suggest that
the expression of KGA is altered at the protein level in the
ACC neurons in subjects with autism. The mechanism by
which KGA expression is reduced in the ACC is
unknown. To the best of our knowledge, this is the first
demonstration of KGA expression in the ACC of post-
mortem brain from individuals with autism. One possible
explanation is that the reduction in the expression of
KGA isozyme may represent an altered function of
glutamatergic neurons in the ACC in subjects with autism.
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ments of amino acids in the present study. Although the
differences in free glutamate and glutamine concentrations
between the two groups did not reach statistical sig-
nificance, the Glu/Gln ratio was lower in autistic
samples compared with controls. This suggests that
the glutamate-glutamine cycle in the ACC may shift toward
glutamine rather than glutamate in autism. These findings
may provide further evidence of impaired glutamatergic
transmission, which was previously implicated in the
pathophysiology of autism [27].
Glutamine is a precursor of glutamate, which is further
converted into γ-aminobutyric acid (GABA) by glutamate
decarboxylase in GABAergic neurons. KGA exists in both
glutamatergic and GABAergic neurons and is involved in
the production of both neurotransmitters [28]. Therefore,
the reduction of KGA expression in our study might have
been the result of alterations not only in glutamatergic but
also in GABAergic neurons. In fact, the density of both
GABAA and GABAB receptors was decreased in the
ACC of individuals with autism [29,30], suggesting
the dysfunction of the GABAergic projection or GABA
release in the ACC.
Neurons in the ACC project to the ventral striatum,
from which projections pass to the globus pallidus, ventral
pallidum, and substantia nigra, the subcortical structures
known to modulate cortical information processing by
different neurotransmitter systems [2,11]. The present
study found a significant reduction in KGA in the ACC,
suggesting that excitatory neurotransmissions through the
ACC would be impaired in autism. The abnormal con-
nectivity passing through the ACC and related regions can
increase the ratio of excitation/inhibition of a wide variety
of brain regions, which is postulated to be the common
pathway for causing autism [31].
The LGA isozyme was originally thought to be present
only in the liver [32]. Recently, LGA was found to be
expressed in astrocytes in the brain, although its functional
role remains to be elucidated [33]. In our study, the expres-
sion levels of LGA, GS, GDH1, and GDH2, all of which are
expressed in astrocytes, were similar in the autism and
control groups. In addition, no significant differences were
observed between the two groups in terms of GFAP expres-
sion levels in the ACC. This finding was consistent with
those of a previous report [34] showing increased expres-
sion of GFAP in the cerebellum, but not in the ACC, in the
postmortem brain of individuals with autism.
The lack of a significant change in tissue levels of
glutamate or glutamine suggests that the regional con-
tents of glutamate and glutamine in the ACC may not
be altered in people with autism. The fact that the tissue
levels of glutamate and glutamine remained constant is
of little importance in this respect, since the tissue level
does not reflect the turnover of the pool of each aminoacid. Indeed, Friedman et al. [17] revealed in a 1H-MRS
study that levels of Glx in the ACC did not differ
between children with ASD and typically-developed
controls. In contrast, DeVito et al. [5] reported finding
widespread Glx reductions in the gray matter of children
with ASD. Using 3T 1H-MRS, Bernardi et al. [16]
demonstrated that adults with ASD showed significantly
lower Glx concentration in the right, but not the left,
ACC compared to controls. Since the samples used in
the present study were all from the left ACC, our results
could be considered consistent with those of Friedman
et al. [17] and Bernardi et al. [16]. Given that there was
no concomitant reduction in other enzymes in the
glutamate-glutamine cycle, most of which are essentially
expressed in astrocytes, the negative result of the tissue
levels of these two amino acids may be attributable to
the compensatory function of astrocytes.Conclusion
In conclusion, this study provides evidence of a reduction
in KGA expression in the ACC of the postmortem brain
of individuals with autism. The finding indicates a dys-
function in excitatory amino acid neurotransmission in
this brain region in the disorder. Since the small sample
size renders the data presented here preliminary, studies
with more subjects with ASD that examine more regions
of the brain than the ACC are necessary.Additional files
Additional file 1: Relationships between age and expression levels
of proteins.
Additional file 2: Relationships between age and concentrations or
ratio of glutamate and glutamine.Abbreviations
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